{
    "clinical_study": {
        "@rank": "146442", 
        "acronym": "CHASE 3", 
        "arm_group": [
            {
                "arm_group_label": "Symbicort pMDI 80/2.25 \u00b5g", 
                "arm_group_type": "Active Comparator", 
                "description": "Budesonide/formoterol pMDI 80/2.25 \u00b5g, 2 acuations twice daily"
            }, 
            {
                "arm_group_label": "Symbicort pMDI 80/4.5\u00b5g", 
                "arm_group_type": "Active Comparator", 
                "description": "Budesonide/formoterol pMDI 80/4.5\u00b5g, 2 acuations twice daily"
            }, 
            {
                "arm_group_label": "Budesonide pMDI", 
                "arm_group_type": "Active Comparator", 
                "description": "Budesonide pMDI 80\u00b5g, 2 acuations twice daily"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose is to investigate the Efficacy and Safety of Symbicort pMDI 80/2.25 \u03bcg and\n      Symbicort pMDI 80/4.5 \u03bcg, Compared with Budesonide pMDI 80 \u03bcg, 2 Actuations Twice Daily, in\n      Children Ages 6 to <12 Years with Asthma during 12 weeks."
        }, 
        "brief_title": "A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 \u03bcg and Symbicort pMDI 80/4.5 \u03bcg, Compared With Budesonide pMDI 80 \u03bcg", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "A Phase 3, 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study\n      Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 \u03bcg, 2 Actuations Twice\n      Daily, and Symbicort pMDI 80/4.5 \u03bcg, 2 Actuations Twice Daily, Compared with Budesonide pMDI\n      80 \u03bcg, 2 Actuations Twice Daily, in Children Ages 6 to <12 Years with Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Has a documented clinical diagnosis of asthma defined by the ATS for at least 6\n             months prior to Visit 2\n\n          -  Have a morning pre-bronchodilator clinic FEV1 measured at least 6 hours after the\n             last dose of inhaled SABA and at least 48 hours after last dose of inhaled LABA of\n             60% to 100% of predicted normal\n\n          -  Demonstrated reversibility of clinic FEV1 of \u226512% from pre -albuterol/salbutamol\n             level within 15 to 30 minutes after administration of a standard dose of\n             albuterol/salbutamol.\n\n        Exclusion Criteria:\n\n          -  Have been hospitalized at least once or required emergency treatment more than once\n             for an asthma-related condition during the 6 months prior to Visit 1\n\n          -  Have required treatment with systemic corticosteroids (eg, oral, parenteral, or\n             rectal) for any reason within the 6 weeks prior to Visit 1"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "11 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "1116", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02091986", 
            "org_study_id": "D589GC00003"
        }, 
        "intervention": [
            {
                "arm_group_label": "Symbicort pMDI 80/2.25 \u00b5g", 
                "description": "Budesonide/formoterol pMDI 80/2.25 \u00b5g, 2 acuations twice daily", 
                "intervention_name": "Symbicort pMDI", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Symbicort pMDI 80/4.5\u00b5g", 
                "description": "Budesonide/formoterol pMDI 80/4.5\u00b5g, 2 acuations twice daily", 
                "intervention_name": "Symbicort pMDI", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Budesonide pMDI", 
                "description": "Budesonide pMDI 80\u00b5g, 2 acuations twice daily", 
                "intervention_name": "Budesonide pMDI", 
                "intervention_type": "Other", 
                "other_name": "Active comparator"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Budesonide", 
                "Symbicort"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "asthma, children, budesonide pMDI", 
        "lastchanged_date": "June 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Huntington Beach", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mission Viejo", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rolling Hills Estate", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockton", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Walton Beach", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockbridge", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bellevue", 
                        "country": "United States", 
                        "state": "Nebraska"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Verona", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rockville Centre", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Medford", 
                        "country": "United States", 
                        "state": "Oregon"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Waco", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fairfax", 
                        "country": "United States", 
                        "state": "Virginia"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Monterrey", 
                        "country": "Mexico"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "David Chiriqui", 
                        "country": "Panama"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Panama", 
                        "country": "Panama"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lucenec", 
                        "country": "Slovakia"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Mexico", 
                "Panama", 
                "Slovakia"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 3, 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 \u03bcg, 2 Actuations Twice Daily, and Symbicort pMDI 80/4.5 \u03bcg, 2 Actuations Twice Daily, Compared With Budesonide pMDI 80 \u03bcg, 2 Actuations Twice Daily, in Children Ages 6 to <12 Years With Asthma", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Carola Halderman", 
            "phone": "+1 913-708-6155"
        }, 
        "overall_official": [
            {
                "affiliation": "Colorado Allergy Asthma Centers, PC, US", 
                "last_name": "David S Pearlman, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "AstraZeneca M\u00f6lndal, Sweden", 
                "last_name": "Carin Jorup, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from baseline to Week 12 in one-hour post-dose FEV1", 
            "measure": "Change from baseline in one-hour post-dose forced expiratory volume in the first second (FEV1)", 
            "safety_issue": "No", 
            "time_frame": "Baseline to Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02091986"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from baseline to one-hour post-dose FVC at Weeks 2, 4, 8 and 12", 
                "measure": "Change from baseline in one-hour post-dose clinic FVC (L)", 
                "safety_issue": "No", 
                "time_frame": "Baseline taken at Week 0 then at Weeks 2, 4, 8 and 12"
            }, 
            {
                "description": "Change from baseline to one-hour post-dose FEF25-75 at Weeks 2, 4, 8 and 12", 
                "measure": "Change from baseline in one-hour post-dose clinic FEF25-75 (L/s) measured in the clinic", 
                "safety_issue": "No", 
                "time_frame": "Baseline taken at Week 0 then at Weeks 2,4,8 and 12"
            }, 
            {
                "description": "Change from baseline to one-hour post-dose PEF at Weeks 2, 4, 8 and 12", 
                "measure": "Change from baseline in one-hour post-dose peak expiratory flow (PEF) (L/min) measured in the clinic (clinic PEF)", 
                "safety_issue": "No", 
                "time_frame": "Baseline taken at Week 0 then at Weeks 2,4,8 and 12"
            }, 
            {
                "description": "Change from baseline in one-hour post dose FEV1 at Weeks 2, 4 and 8", 
                "measure": "Change from baseline in one-hour post-dose FEV1", 
                "safety_issue": "No", 
                "time_frame": "Weeks 2, 4 and 8"
            }, 
            {
                "description": "Change from baseline to pre-dose FEV1 at Weeks 2,4,8 and 12", 
                "measure": "Change from baseline in pre-dose clinic FEV1 in liter (L).", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 2,4,8 and12"
            }, 
            {
                "description": "Change from baseline to pre-dose FVC (L) at Weeks 2,4,8 and 12", 
                "measure": "Change from baseline in pre-dose clinic FVC (L)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 2,4,8 and12"
            }, 
            {
                "description": "Change from baseline to pre-dose FEF25-75 at Weeks 2,4,8 and 12", 
                "measure": "Change from baseline in pre-dose clinic FEF25-75 (L/s)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 2,4,8 and12"
            }, 
            {
                "description": "Change from baseline to pre-dose PEF at Weeks 2, 4, 8 and 12", 
                "measure": "Change from baseline in pre-dose clinic Peak expiratory flow (PEF) (L/min)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 2, 4, 8 and12"
            }, 
            {
                "description": "Change from baseline to one-hour post-dose FEV1 at Week 12", 
                "measure": "Change from baseline in fifteen-minute post-dose clinic FEV1 (L)", 
                "safety_issue": "No", 
                "time_frame": "Baseline taken at Week 0 then at Week 12."
            }, 
            {
                "description": "Change from baseline to one-hour post-dose FVC at Week 12", 
                "measure": "Change from baseline in fifteen-minute post-dose clinic clinic FVC (L)", 
                "safety_issue": "No", 
                "time_frame": "Baseline taken at Week 0 then at Week 12."
            }, 
            {
                "description": "Change from baseline to one-hour post-dose FEF25-75 at Week 12", 
                "measure": "Change from baseline in fifteen-minute post-dose clinic FEF25-75 (L/s)", 
                "safety_issue": "No", 
                "time_frame": "Baseline taken at Week 0 then at Week 12."
            }, 
            {
                "description": "Change from baseline to one-hour post-dose clinic PEF (L/min) at Week 12", 
                "measure": "Change from baseline in fifteen-minute post-dose clinic PEF (L/min)", 
                "safety_issue": "No", 
                "time_frame": "Baseline taken at Week 0 then at Week 12."
            }, 
            {
                "description": "Time in days from randomization until first exacerbation during the 12-week treatment period.", 
                "measure": "Time to occurrence of first asthma exacerbation", 
                "safety_issue": "No", 
                "time_frame": "Randomized 12-week treatment period"
            }, 
            {
                "description": "Change in percentage of nighttime awakenings from baseline Treatment Week 12", 
                "measure": "Change from baseline in nighttime awakenings due to asthma symptoms requiring reliever use recorded in the eDiary during the single blind run in and the double blind treatment periods", 
                "safety_issue": "No", 
                "time_frame": "Baseline taken as percentage of nighttime awakenings during the last 7 days of run-in. Week 12 taken as percentage of nighttime awakenings during Treatment Week 12."
            }, 
            {
                "description": "Change from baseline PAQLQ(S) to mean of Weeks 4, 8 and 12", 
                "measure": "Change from baseline in paediatric Asthma Quality of Life Questionnaire with Standardised Activities (PAQLQ[S]) scores (overall and each domain)", 
                "safety_issue": "No", 
                "time_frame": "Baseline taken at Week 0 then at Weeks 4, 8 and 12"
            }, 
            {
                "description": "Change from baseline mean in diary FEV1 to mean at Week 12", 
                "measure": "Change from baseline in morning and evening FEV1 (L) recorded in the electronic diary (eDiary)", 
                "safety_issue": "No", 
                "time_frame": "Baseline taken as the mean of the last 7 days of the run-in period. Week 12 taken as the mean during Week 12 of the treatment period."
            }, 
            {
                "description": "Change from mean baseline to Treatment Week 12 mean in nighttime reliever medication use.", 
                "measure": "Change from baseline in nighttime reliever medication use recorded in the eDiary", 
                "safety_issue": "No", 
                "time_frame": "Baseline taken as the mean of the last 7 days of the run-in period. Week 12 taken as the mean during Week 12 of the treatment period."
            }, 
            {
                "description": "Change from mean baseline to Treatment Week 12 mean in daytime reliever medication use.", 
                "measure": "Change from baseline in daytime reliever medication use recorded in the eDiary", 
                "safety_issue": "No", 
                "time_frame": "Baseline taken as the mean of the last 7 days of the run-in period. Week 12 taken as the mean during Week 12 of the treatment period."
            }, 
            {
                "description": "Change from mean baseline to Treatment Week 12 mean in total reliever medication use.", 
                "measure": "Change from baseline in total daily reliever medication use recorded in the eDiary", 
                "safety_issue": "No", 
                "time_frame": "Baseline taken as the mean of the last 7 days of the run-in period. Week 12 taken as the mean during Week 12 of the treatment period."
            }, 
            {
                "description": "Change from mean baseline score to mean score during Week 12", 
                "measure": "Change from baseline in nighttime asthma symptom scores recorded in the eDiary", 
                "safety_issue": "No", 
                "time_frame": "Baseline taken as the mean of the last 7 days of the run-in period. Week 12 taken as the mean during Week 12 of the treatment period."
            }, 
            {
                "description": "Change from mean baseline score to mean score during Week 12", 
                "measure": "Change from baseline in daytime asthma symptom scores recorded in the eDiary", 
                "safety_issue": "No", 
                "time_frame": "Baseline taken as the mean of the last 7 days of the run-in period. Week 12 taken as the mean during Week 12 of the treatment period."
            }, 
            {
                "description": "Change from mean baseline score to mean score during Week 12", 
                "measure": "Change from baseline in total daily asthma symptom scores recorded in the eDiary", 
                "safety_issue": "No", 
                "time_frame": "Baseline taken as the mean of the last 7 days of the run-in period. Week 12 taken as the mean during Week 12 of the treatment period."
            }, 
            {
                "description": "Time in days from randomization until discontinuation of investigational product during the 12-week treatment period", 
                "measure": "Time to discontinuation of investigational product (IP).", 
                "safety_issue": "No", 
                "time_frame": "Randomized 12-week treatment period"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}